Closed · RFA-CA-10-013 · CFDA 93.393;93.394;93.395;93.396 · Discretionary
Innovative Emerging Molecular Analysis Technologies (SBIR R43/R44)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- February 8, 2011
- Close date
- -
- Expected awards
The verdict
Innovative Emerging Molecular Analysis Technologies (SBIR R43/R44) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- Varies
- award range
- Closed
- application status
- 93.393;93.394;93.395;93.396
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
Innovative Emerging Molecular Analysis Techno… is closed (last close February 8, 2011). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed February 8, 2011
Est. Total Funding
$2,000,000
Instrument
Grant
Description
Purpose. This Funding Opportunity Announcement (FOA) solicits grant applications from small business concerns (SBCs) proposing research towards commercial development of emerging molecular and/or cellular analytical technologies intended for cancer detection and/or characterization. The goal of this FOA is to facilitate the translation of innovative, cancer-relevant technologies into commercial products and/or services. The emphasis is on molecular analysis technologies to improve cancer prevention, detection and diagnosis, surveillance, epidemiological research, and basic cancer research. These technologies may be intended for molecular and cellular analyses in vitro, in situ, and/or in vivo. There must be sound rationale pointing to the commercial potential of the technology to be developed. Mechanism of Support. This FOA will utilize the SBIR R43/R44 grant mechanisms for Phase I, Phase II, and Fast-Track applications. Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of five to seven projects awarded under this announcement is $2 million for fiscal year 2011. Future year amounts will depend on annual appropriations.
Small-business / for-profit corridor · RFA-CA-10-013
Innovative Emerging Molecular Analysis Techno… prints a for-profit / small-business applicant door (Small businesses). Treat the listing as business-facing unless the full Grants.gov announcement narrows it further. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity codes span Education · Health (ED;HL). 789 other National Institutes of Health listings share this eligibility-code string (6% of 12,420).
- Code 23
- Small businesses
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Innovative Emerging Molecular Analysis Techno… is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 93.393;93.394;93.395;93.396 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |